In this episode, we discuss the management of follicular lymphoma with Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. Here are the articles we discussed: 1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/ 2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/ 3. Long-term follow-up results of RCT comparing early rituximab...
Jul 25, 2025•52 min•Ep. 64
In this episode, we dissect the phase 3 MIDAS trial in newly diagnosed transplant-eligible multiple myeloma with Dr. Meera Mohan. https://pubmed.ncbi.nlm.nih.gov/39841461/ https://pubmed.ncbi.nlm.nih.gov/40459097/
Jul 09, 2025•25 min•Ep. 63
In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022 Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6 DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/Th...
Jun 24, 2025•56 min•Ep. 62
In this episode, we discuss the recent proceedings at the FDA ODAC meeting on AQUILA trial in smoldering myeloma and STRAGLO in R/R DLBCL, and provide an update to our audience on some of the clinically relevant data presented from those trials, along with insights from the panelists. Here is the link to the webpage with FDA briefing documents and slides: https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025#event-m...
May 28, 2025•55 min•Ep. 61
In this episode, we discussed the management of systemic mastocytosis with Dr. Daniel DeAngelo from the Dana Farber Cancer Institute. Here are the key studies we discussed: Midostaurin https://www.nejm.org/doi/10.1056/NEJMoa1513098?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov Avapritinib EXLPORER study: https://www.nature.com/articles/s41591-021-01538-9 PATHFINDER study: https://www.nature.com/articles/s41591-021-01539-8 Bezuclastinib: APEX tr...
May 08, 2025•1 hr 3 min•Ep. 60
In this episode, we explore the emerging entity of CAR Transgenic T-cell Lymphoproliferative Neoplasms (CTTLN), a rare but important complication of CAR T-cell therapy. Dr. Piers Blombery from Peter MacCallum Cancer Center joins us to dissect two cases from the CARTITUDE-4 trial where patients developed T-cell lymphomas expressing the chimeric antigen receptor following cilta-cel treatment for multiple myeloma. As a bonus, we also briefly discussed Dr. Blombery’s paper on menin inhibitors in UBT...
Mar 26, 2025•50 min•Ep. 59
In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3 Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.html Abstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.html Abstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.html Venetoclax resistance mechanisms http...
Mar 19, 2025•55 min•Ep. 58
In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. https://pubmed.ncbi.nlm.nih.gov/38820078/ 2. 5-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/26837842/ 3. 10-year follow-up of ENESTnd RCT (nilotinib): https://pubmed.ncbi.nlm.nih.gov/33414482/ 4. 10-year follow-up of CML-IV RCT (imatinib): https://pubmed.ncbi.nlm.nih.go...
Feb 12, 2025•1 hr 3 min•Ep. 57
In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed: 1. AQUILA Trial in High-Risk SMM Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring. Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara. Insights into modes of ...
Jan 11, 2025•38 min•Ep. 56
In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.html b) ENRICH Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.html c) ECOG-ACRIN EA4151 Trial...
Dec 22, 2024•58 min•Ep. 55
In this episode, we discuss the comeback of belantamab mafadotin in multiple myeloma with Dr. Hang Quach, along with some other important abstracts presented at EHA/ASCO 2024. Here are the studies we discussed: 1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/ 2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/ 3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/ ...
Nov 13, 2024•45 min•Ep. 54
In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/ 2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/ 3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/ 4. SWOG S1826 trial (Nivo-AVD vs AAVD in advan...
Oct 26, 2024•42 min•Ep. 53
In this episode, we discuss the history of venetoclax in AML, along with key clinical trials that have shaped its current use in AML. Here are the trials discussed in this episode: 1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971 2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract 3. Genetic Risk Stratification and Outcomes with AML treated with venetoclax and azacitidine https://ashpublications-...
Sep 27, 2024•57 min•Ep. 52
In this episode, we discuss the management of newly diagnosed transplant in-eligible multiple myeloma with Dr. Timothy Schmidt, with a special focus on IMROZ and BENEFIT RCTs testing quadruplets in this space. Here are the key papers we discussed: 1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/ 2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-def...
Aug 29, 2024•42 min•Ep. 51
In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. Here are the trials we discussed: 1. IWG 2019 response criteria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 2. MEDALIST trial: Luspatercept https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 3. COMMANDS trial : Luspatercept https://www.thelancet.com/journals/lancet/article/PIIS0140-6736...
Aug 14, 2024•43 min•Ep. 50
In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell 3. MAJIC PV study https://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 4...
Jul 21, 2024•57 min•Ep. 49
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library.ehaweb.org/eha/2024/eha2024-congress/4136516 2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study): https://library.ehaweb.org/eha/2024/eha2024-...
Jul 06, 2024•48 min•Ep. 48
In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1. Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL0 2. EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: ...
Jun 09, 2024•58 min•Ep. 47
In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS : Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0 : Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis § https://ascopubs.org/doi/10.1200/JCO.2018.78.9867?url_ver=Z3...
May 29, 2024•1 hr 1 min•Ep. 46
In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. Myeloma XI RCT (lenalidomide vs observation): https://pubmed.ncbi.nlm.nih.gov/30559051/ 3. Outcomes of lenalidomide maintenance stratified by cytogeneti...
May 01, 2024•53 min•Ep. 45
In this episode, we discuss the diagnosis and management of Essential Thrombocythemia with Dr. Raajit Rampal. Here are the shownotes: 1. IPSET (revised) system , risk categories are defined by the presence of a prior thrombosis, age, and JAK2 mutation status: · Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated · Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated · Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated · High risk: History of thrombosis (any ag...
Apr 18, 2024•35 min•Ep. 44
In this episode, we talked about overall survival data from CARTITUDE-4 and KarMMa-3 that was presented at FDA ODAC meeting with Dr. Samer Al Hadidi from University of Arkansas Myeloma Center. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma: a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/ b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/ FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4: https://www.youtube.com/watch?v=VSjdGee...
Mar 27, 2024•55 min•Ep. 43
In this episode, we discuss mentorship and career development as a clinician-investigator with Dr. Ayalew Tefferi from the Mayo Clinic.
Mar 14, 2024•47 min•Ep. 42
In this episode we discuss the management of newly diagnosed AL amyloidosis with Dr. Angela Dispenzieri from the Mayo Clinic. Here are the key articles discussed: 1. Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/ 2. Mayo 2004 staging: https://pubmed.ncbi.nlm.nih.gov/15365071/ 3. Mayo 2012 staging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/ 4. Renal staging: https://pubmed.ncbi.nlm.nih.gov/25115890/ 5. Hematologic and cardiac response criteria...
Feb 21, 2024•53 min•Ep. 41
In this episode, we discuss top abstracts in the myeloid space from the American Society of Hematology 2023 meeting with Dr. Anand Patel. Here are the abstracts that were discussed: 1. TRANSFORM-1 : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis https://ash.confex.com/ash/2023/webprogram/Paper173509.html 2. MANIFEST-2 : Pelabresib in Com...
Feb 08, 2024•55 min•Ep. 39
In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. Here are the key trials we discussed: 1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation. ...
Jan 19, 2024•52 min•Ep. 40
In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: First, we will focus on a few abstracts in precursor states, MGUS. 1. New diagnostic criteria for light chain MGUS (IStopMM): https://ash.confex.com/ash/2023/webprogram/Paper188547.html https://ash.confex.com/ash/2023/webprogram/Paper182661.html 2. PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myelom...
Dec 27, 2023•1 hr 2 min•Ep. 38
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ib...
Dec 20, 2023•51 min•Ep. 37
In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL: https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL: https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL: https://pubmed.ncbi....
Nov 30, 2023•1 hr 9 min•Ep. 36
In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl. Here are the shownotes: 1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation https://www.nejm.org/doi/full/10.1056/nejmoa1614359 3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-dupli...
Nov 17, 2023•1 hr 8 min•Ep. 35
